Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
In each group: 1) To evaluate compliance, in terms of immunogenicity, of the corresponding strength of the ID influenza vaccine NH 2010-2011 formulation with the requirements of the Committee for Proprietary Medicinal Products (CPMP) Note for Guidance (NfG) CPMP/BWP/214/96 2) To describe the safety of the corresponding strength of the ID influenza vaccine, NH 2010-2011 formulation
Inclusion criteria
- Vaccination of adults up to 59 years of age and elderly of 60 years of age and over with inactivated split-virion influenza vaccine administered by the intraderma route